Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TYRA-300 in FGFR3 Altered Low Grade, Intermediate Risk NMIBC
NCT06995677Phase 2Recruiting
- Sponsor
- Tyra Biosciences
- Start
- Jun 2025
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of dabogratinib in non-muscle-invasive bladder cancer (NMIBC), sponsored by Tyra Biosciences. Started Jun 2025; status: recruiting.
02
Drugs
dabogratinib
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT06995677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06995677.